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Abstract
Introduction: Sorafenib, a multitarget kinase inhibitor, targets members of the mitogen-activated protein kinase (MAPK)
pathway and VEGFR kinases. Here we assessed the association between expression of sorafenib targets and biomarkers of
taxane sensitivity and response to therapy in pre-treatment tumors from patients enrolled in ECOG 2603, a phase III
comparing sorafenib, carboplatin and paclitaxel (SCP) to carboplatin, paclitaxel and placebo (CP).
Methods: Using a method of automated quantitative analysis (AQUA) of in situ protein expression, we quantified expression
of VEGF-R2, VEGF-R1, VEGF-R3, FGF-R1, PDGF-Rb, c-Kit, B-Raf, C-Raf, MEK1, ERK1/2, STMN1, MAP2, EB1 and Bcl-2 in
pretreatment specimens from 263 patients.
Results: An association was found between high FGF-R1 and VEGF-R1 and increased progression-free survival (PFS) and
overall survival (OS) in our combined cohort (SCP and CP arms). Expression of FGF-R1 and VEGF-R1 was higher in patients
who responded to therapy ((CR+PR) vs. (SD+PD+ un-evaluable)).
Conclusions: In light of the absence of treatment effect associated with sorafenib, the association found between FGF-R1
and VEGF-R1 expression and OS, PFS and response might reflect a predictive biomarker signature for carboplatin/paclitaxel-
based therapy. Seeing that carboplatin and pacitaxel are now widely used for this disease, corroboration in another cohort
might enable us to improve the therapeutic ratio of this regimen.
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Introduction
The incidence of melanoma is rising faster than that of any
other malignancy; the incidence of metastatic disease and death
are rising as well [1]. Treatment of advanced disease has been a
challenge and so far has shown only limited efficacy. Until 2010,
no therapies studied in randomized trials had an impact on OS,
including chemotherapy, biological therapies and combinations of
both. [2]. Recently, a monoclonal antibody that inhibits CTLA-4,
ipilimumab (Bristol Myers Squibb and Medarex Incorporated),
showed durable objective responses and improved median survival
in some patients when compared with a peptide vaccine or DTIC
[3,4]. The second major recent advance was in selective targeting
of mutated B-Raf. The MAPK pathway is activated in the
majority of human melanomas and plays a critical role in
regulating the proliferation, invasion and survival of melanoma
cells; approximately half of the melanomas harbor activating
mutations in B-Raf and 15–20% have mutations in NRAS [5].
Thus, drugs that target the MAPK pathway have been the focus of
intense clinical research. One selective inhibitor of mutant B-Raf,
PLX4032 (RG7204/RO5185426/Vemurafenib, Genentech) has
been recently approved for treatment of metastatic melanoma
after showing remarkable clinical activity in patients with mutated
B-Raf when compared to dacarbazine [6]. Other MAPK pathway
inhibitors, such as GSK2118436 (Dabrafenib, GlaxoSmithKline),
also a selective inhibitor of mutant B-Raf, and GSK1120212
(Trametinib, GlaxoSmithKline), a potent MEK inhibitor, have
been investigated in advanced clinical trials for patients with
melanoma harboring B-Raf mutations and showed to improve
survival when compared to chemotherapy [7,8].
Sorafenib (BAY 43-9006, Nexavar, Bayer Pharmaceuticals
Corporation & Onyx Pharmaceuticals) is an orally active,
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unselective, multikinase agent that inhibits C-Raf and B-Raf
(mutant and wild type) along with a number of other cellular
proteins involved in tumor neovascularization and tumor cell
proliferation and survival, including VEGFR-2, VEGFR-3, Flt3,
FGFR1, PDGFR-b, c-Kit and p38a [9]. Sorafenib is FDA
approved for treatment of advanced renal cell carcinoma (RCC)
and hepatocellular carcinoma (HCC) [10,11]. In pre-clinical
melanoma models (cell lines and tumor xenografts) sorafenib
slowed cellular proliferation and tumor growth through inhibitory
effects on the MAPK pathway [9,12,13,14,15]. Sorafenib was
therefore felt to be a reasonable drug to study in melanoma. In
clinical trials, single agent sorafenib had little activity in melanoma
patients, with response rates of less than 10% in two early phase
studies [16,17]. However, in a phase I multi-tumor study in which
sorafenib was combined with carboplatin and paclitaxel (SCP), a
number of responses were seen in melanoma patients, leading to
an expanded phase I/II trial of SCP in melanoma [18]. This study
demonstrated an overall response rate of 26% in melanoma
patients and a median PFS of 307 days, a result that required
validation in a phase III trial. Two such trials were conducted; a
second line therapy study in which SCP was compared to
carboplatin, paclitaxel and placebo (CP) and a cooperative group
study for patients who were chemotherapy-naive led by the
Eastern Cooperative Oncology Group (ECOG), called E2603
[19,20,21]. Both of these trials failed to demonstrate a benefit in
OS or PFS for SCP versus CP plus placebo.
Retrospective analysis of B-Raf mutational status in patients
treated on the phase I/II trial showed no difference in activity of
SCP in patients with B-Raf mutated tumors compared to B-Raf
wild-type (WT) tumors [18]. To identify potential predictors of
response to SCP, we previously quantitatively assessed the
expression of targets of sorafenib in pretreatment tumors from
44 patients enrolled in the phase I/II trial of this multidrug
regimen. In this small cohort we found that high levels of VEGF-
R2 and low ERK1/2 levels were associated with a greater
likelihood of response in patients treated with SCP [22]. that none
of the patients in this cohort were treated with CP alone, it was
unclear whether this association was related to chemotherapy
sensitivity or sensitivity to the combination regimen.
The purpose of this current study was to assess expression of
direct and indirect sorafenib targets in pretreatment specimens
from patients enrolled in E2603. We also assessed expression levels
of select molecules that have previously been shown to be
associated with sensitivity to taxane drugs (Stathmin (STMN1),
Microtubule-associated protein 2 (MAP2), End-binding protein
1(EB1) and Bcl-2). Specimens were available for 263 patients. We
evaluated the association between marker expression and efficacy
outcomes (objective response rate (ORR), OS and PFS) in the 263
patients. Marker expression was assessed using an objective,
method of automated, quantitative analysis, AQUA (Automated
Quantitative Analysis). This method has been validated for
epithelial cancers and melanoma and proven to be superior to
pathologist-based scoring of 3,3’-diaminobenzidine stain in that it
is more precise, highly reproducible and quantitative [23,24].
Materials and Methods
Patients and study design
E2603 enrolled 823 patients. Specimen collection was conduct-
ed as part of the trial and analyzed with institutional review board
approval. All patients had pathologically confirmed advanced
unresectable or metastatic melanoma without brain involvement
and had not previously been treated with chemotherapy or MAPK
pathway targeted drugs. The study design, including the patient
details, has been described previously [21]. Patients had measure-
able disease by RECIST, were at least 18 years of age, had an
ECOG performance status of 0 or 1, and satisfactory baseline
organ function. Patients were enrolled without determination of B-
Raf or N-Ras mutational status.
Treatment and assessment of response
Patients were randomized in a double-blinded fashion to receive
either SCP or CP. On day 1 of each 21 day cycle (cycles 1 through
4), paclitaxel was administered at 225 mg/m2 IV over 3 hours
followed by carboplatin AUC 6 IV over 30 minutes. Sorafenib
(400 mg) or placebo was given by mouth twice daily days 2
through 19 of each 21 day cycle. On day 1 of each 21 day cycle
(cycles 5 through 10), paclitaxel was administered at 175 mg/m2
IV over 3 hours followed by carboplatin AUC 5 IV over 30
minutes. Sorafenib (400 mg) or placebo was given by mouth twice
daily on days 2 through 19 of each 21 day cycle. Upon completion
of 10 cycles of chemotherapy, Sorafenib (400 mg BID) or placebo
was administered daily until disease progression or intolerable
toxicity.
Tumor response was assessed every 2 cycles during cycle 1 to 10
and then every 3 cycles. Response was defined by RECIST.
Tissue microarray (TMA) construction
Pre-treatment formalin-fixed paraffin embedded tumor biopsies
were obtained from patients as part of the clinical trial. A
pathologist (DLR) examined each case and selected a represen-
tative region of invasive tumor to be included in the array.
Adequate tissue was available on 263 patients. Two cores from
each block were taken to construct the TMAs as previously
described [25,26]. Cores measuring 0.6 mm in diameter, were
spaced 0.8 mm apart. The tissue microarrays were cut into 5-mm
sections and placed on glass slides using an adhesive tape-transfer
system with UV cross-linking. To account for experimental
variation and for normalization across array blocks, pellets of
melanoma cell lines were embedded in all array blocks, as
described previously [27].
Immunofluorescence
One set of two slides (each containing a core from different
areas of tumor for the same patient) was stained for VEGF-R2,
VEGF-R1, VEGF-R3, FGF-R1, PDGF-Rb, c-Kit, B-Raf, C-Raf,
MEK1, ERK1/2, STMN1, MAP2, EB1 and Bcl-2. Staining was
carried out for AQUA as described [25,28]. A list of antibodies
and manufacturers is supplied in Table S1 in File S1. Briefly, slides
were deparaffinized in xylene followed by two rinses in 100%
ethanol. Antigen retrieval was performed by boiling slides in a
pressure cooker filled with 6.5 mM sodium citrate (pH 6.0). Slides
were incubated in a mixture of methanol and 2.5% hydrogen
peroxide for thirty minutes at room temperature to block the
endogenous peroxidase activity. To block non-specific staining,
slides were then incubated at room temperature for 30 minutes in
0.3% bovine serum albumin/1X Tris-buffered saline. Slides were
incubated with the primary antibody diluted in Tris-buffered
saline containing 0.3% bovine serum albumin at 4uC overnight.
Slides were then washed three times in 1X Tris-buffered saline/
0.05% Tween-20. Either goat anti-mouse (for rabbit primary
antibodies) or goat anti-rabbit (for mouse primary antibodies)
horseradish peroxidase-decorated polymer backbone (Envision,
Dako) was utilized to visualize the target protein. To create a
tumor mask, slides were simultaneously incubated with either
mouse or rabbit anti-S100 and anti-HMB45, at 1:100. For
visualization of tumor mask staining a goat anti-mouse or anti-
rabbit IgG conjugated to Alexa 546 (Molecular Probes, Inc.) at
Melanoma Drug Targets
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1:200 was utilized. Primary antibody staining was visualized with
Cy5-tyramide (NED Life Science Products). Coverslips were
mounted with ProLong Gold antifade reagent with 49,6-diami-
dino-2-phenylindole (DAPI) (Invitrogen).
Automated image acquisition and analysis
Images were analyzed using algorithms that have been
extensively described [23]. Briefly, monochromatic, high-resolu-
tion (128061024 pixel) images were obtained of each histospot.
Tumor was distinguished from stromal elements by S-100 and
HMB45 signal. Coalescence of S-100 and HMB45 at the cell
surface was used to localize cell membrane/cytoplasm compart-
ment within the tumor mask, and DAPI was used to identify the
nuclear compartment within the tumor mask. Targets were
visualized with Cy5. Images were obtained for each histospot
using the 10X objective of an Olympus AX-51 epifluorescence
microscope (Olympus, Melville, NY) with an automated micro-
scope stage and digital image acquisition driven by custom
program and macrobased interfaces with IPLabs software
(Scanalytics, Inc., Fairfax, VA). The signal intensity for all targets
was scored on a scale of 0–255 (the AQUA score). Histospots with
limited amount of tumor tissue (,3%) were excluded from the
analysis.
Data analysis
Expression of markers was analyzed using either continuous
AQUA scores or variables dichotomized at the median, reflecting
the use of routine statistical divisions in the absence of an
underlying justification for division of expression. The Pearson
correlation test was used to compare AQUA scores for markers
from matching spots from the two arrays. The association between
dichotomized markers and objective response status (complete
response (CR)+ partial response (PR) vs. stable disease (SD)+
progressive disease (PD)+ un-evaluable) and clinical/pathological
parameters (AJCC stage, ECOG performance status, LHD level,
prior therapy) was examined by the Fisher’s exact test. The
association between continuous AQUA scores and objective
response and clinical/pathological parameters was assessed by
two-sample t tests (objective response, ECOG PS and LDH level)
and analysis of variance (AJCC stage and prior treatment).
Kaplan-Meier methods were used to estimate OS and PFS
distribution, and log-rank test was used to test significance in
distribution difference between patients with high or low scores for
each marker (dichotomized at median) or between treatment arms.
OS was defined as time from randomization to death from any
cause, censoring patients that were alive at the last follow-up date.
PFS was defined as time from randomization to disease
progression or death (whichever occurred first), censoring cases
without progression at the date of last disease assessment.
Univariate Cox proportional hazards methods were used to
estimate the unadjusted hazards ratios for OS and PFS for all
markers using continuous AQUA scores and dichotomized
variables. For markers which were significant on univariate
analysis for OS or PFS, multivariable Cox models were used to
estimate the adjusted hazard ratios (dichotomized at median),
adjusting for AJCC stage, ECOG PS, prior treatment, number of
disease sites involved, and LDH.
All p-values were two sided and confidence intervals were at the
95% level. No adjustment was made for multiple comparisons.
SAS version 9.2 software was used for all analysis (SAS, Cary,
NC).
Ethics statement
This work was approved by the Yale University Institutional
Review Board. In addition, approval was obtained through the
Eastern Cooperative Oncology Group (ECOG) for use of and
clinical data from patients enrolled in E2603 clinical trial. Written
informed consent was obtained from all patients on this trial.
Results
The demographics for the 263 patients are summarized in
Table S2 in File S1. There was no statistically significant difference
regarding known prognostic factors between the 263 patients and
the 560 patients without the biomarker data (excluded from the
current report). The two groups of patients also had similar
outcomes (Table S3 in File S1).
To assess the association between marker expression and
clinical response to therapy, we stained our TMAs with antibodies
to VEGF-R2, VEGF-R1, VEGF-R3, FGF-R1, PDGF-Rb, c-Kit,
B-Raf, C-Raf, MEK1, ERK1/2, STMN1, MAP2, EB1 and Bcl-2.
Antibodies were previously validated by Western blots of lysates
obtained from a panel of melanoma cell lines to verify specificity
[22] (antibody specifications are provided in Table S1 in File S1).
We note that a paper was recently published suggesting the
VEGF-R2 antibody by Santa Cruz Technologies used in our
previous paper was not specific, and that another antibody made
by Cell Signaling Technologies was superior. We therefore
purchased the Cell Signaling antibody and found the staining
with this antibody to be non-specific and irreproducible, while the
Western blot using the Santa Cruz antibody yielded a single band
of the appropriate size and staining was both reproducible and
specific. We therefore used the Santa Cruz antibody for these
studies. With the exception of ERK1/2 which showed both
nuclear and cytoplasmic staining, all markers were membranous/
cytoplasmic and this compartment was therefore analyzed.
Staining patterns within the tumor mask within a histospot were
fairly homogenous for all markers analyzed. The range of AQUA
scores and mean values for each marker are provided in Table S4
in File S1. We used the Pearson correlation test to compare scores
from matching spots from the two arrays. For all markers,
expression on two matching specimens from the different arrays
was found to be highly correlated (R values .0.5 and P,0.0001
for all). For patients with multiple available blocks, the different
blocks were cored and AQUA scores were averaged to give one
AQUA score per patient. For each of the markers, the AQUA
scores from both sets of slides were combined to give a single
dataset. Tumor spots were deemed un-interpretable if they had
insufficient tumor cells, loss of tissue in the spot, or an abundance
of necrotic tissue. For patients who had two interpretable
histospots, a composite score was formed by calculating the mean
of the two scores. For patients with only one interpretable core, the
single score was used for analysis. Tumor specimens were available
for a total of 335 patients in E2603, of which 72 had tumors that
were too small or too necrotic for use in the biomarker studies and
therefore 263 patients with interpretable histospots were included
in the current analysis. The sample size for the combined dataset
for each marker is provided in Table S4 in File S1.
We assessed associations between sorafenib targets by Pearson
correlation, as demonstrated in Table S5 in File S1. Expression of
most of the markers was found to be correlated, as expected, given
that many of them are in the MAPK pathway.
Among the patients with available tissue, the ORR, which
included CR and PR, was not statistically different between the
SCP (123 patients) and CP (140 patients) arms (17.9% vs. 16.4%,
P=0.87). Of these, 24 patients (11/123 on SCP arm and 13/140
Melanoma Drug Targets
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on CP arm) had an un-evaluable tumor response. We also found
no difference in OS and PFS between the two arms (Figure 1).
These results indicate that activity of SCP and CP in the group of
patients with available tissue was similar to that of the entire
patient cohort.
In our previous studies on a subset of specimens of patients
treated with SCP in the phase I/II trial, we found that low ERK1/
2 levels were associated with improved ORR, OS and PFS
compared to high ERK1/2 levels, whereas high VEGF-R2 levels
were associated with a higher ORR to SCP. the E2603 treated
patients, low ERK1/2 or/and high VEGF-R2 were not signifi-
cantly associated with better clinical outcomes or increased ORR,
PFS and OS in the SCP arm. To assess the combined effect of
high VEGF-R2 and low ERK1/2 on response, we next generated
a composite VEGF-R2/ERK1/2 score by dichotomizing AQUA
scores by the associated median score for each marker, as we did
previously [22]. We then defined three groups of patients: one
group had low VEGF-R2 and high ERK1/2 expression, the
second group had either low VEGF-R2 and low ERK1/2 or high
VEGF-R2 and high ERK1/2, and the third group had high
VEGF-R2 and low ERK1/2. We found no association between
this composite VEGF-R2/ERK1/2 score and ORR (P=0.15 for
all patients; P=0.60 for SCP arm, P=0.22 for CP arm). The
phase I/II trial with SCP included more patients with a worse
prognosis and high LDH. We therefore studied the association
between the composite VEGF-R2/ERK1/2 score and tumor
response (ORR) in patients with an elevated LDH at registration
(81 patients), and there was no significant association (P=0.30 for
all patients, P=0.29 for SCP arm, P=0.23 for CP arm).
Since expression of ERK1/2 and/or VEGF-R2 was not
associated with response or survival in the sorafenib arm and
since distributions of OS and PFS between the two arms were
similar, we combined the two patient sub-sets and tested
associations between marker expression and response or survival
in the whole cohort of 263 patients. We note that the patients in
the two treatment arms were well balanced in regard to response,
survival and other clinical variables, and no significant differences
were noted between the subsets on the two arms (Tables S2 and S3
in File S1). To assess the association between marker expression
and ORR we performed two-sample t test using the continuous
AQUA scores comparing responders (CR+PR) with non-respond-
ers (SD+PD+ un-evaluable). The expression of VEGF-R1 was
significantly higher in patients who responded to therapy (CR+PR)
than in non-responding patients (P=0.02) (Table 1). A trend
toward significance was seen for FGF-R1 (P=0.08). Although
expression of ERK1/2 was slightly lower in patients who achieved
a clinical response, this association did not reach statistical
significance (P=0.27). There was no statistically significant
association between tumor expression of other markers and
response to therapy (Table 1). When dichotomized marker score
was used, VEGF-R1 expression was significantly correlated with
response (69.4% responders had high expression of VEGF-R1,
Figure 1. Kaplan-Meier survival analysis by treatment arm. Panel A shows Kaplan-Meier estimates of overall survival while panel B shows
Kaplan-Meier estimates of progression-free survival for patients treated with sorafenib, carboplatin and paclitaxel (SCP) or carboplatin and paclitaxel
(CP).
doi:10.1371/journal.pone.0069748.g001
Table 1. Average level of expression for each biomarker
(continuous AQUA scores) by response status.
Non-Responders Responders
Marker Mean SD Mean SD P value
B-Raf 45.5 16.8 46.7 14.4 0.71
c-Kit 38.8 13.1 38.6 10.5 0.93
C-Raf 25.9 11.5 23.8 9.3 0.29
FGF-R1 68.1 16.5 73.0 16.3 0.08
VEGF-R1 33.2 14.3 39.6 17.7 0.02
VEGF-R3 51.6 18.1 55.0 19.4 0.28
MEK1 40.2 16.6 40.7 16.2 0.86
PDGF-Rb 42.5 15.1 42.7 11.7 0.92
STMN1 55.6 19.8 57.0 16.3 0.72
MAP2 24.8 19.4 29.1 24.2 0.30
EB1 37.4 19.4 37.5 19.5 0.99
Bcl-2 27.2 18.9 22.3 13.2 0.13
ERK1/2 36.4 18.5 32.8 13.1 0.27
VEGF-R2 30.5 10.5 30.1 10.7 0.84
Note: P values were generated from two- independent sample t tests.
doi:10.1371/journal.pone.0069748.t001
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and the proportion was 46.0% in non-responders, P=0.011). For
all other markers, there was no significant association.
To assess the association between marker expression and
clinical/pathological parameters at registration, we used two-
sample t tests for ECOG PS (0 vs. 1–2) and LDH level (normal vs.
elevated) and analysis of variance for AJCC stage (Stage III, M1a/
1b, M1c) and prior treatment (none, IFN/IL-2/GM-CSF, one
investigational therapy). We found that high VEGF-R2, high EB1
and high PDGF-Rb expression were significantly correlated with
more advanced AJCC stage (P=0.0099, P=0.0087, P=0.032,
respectively). VEGF-R1 expression was significantly associated
with no prior treatment (P=0.027) (Table 2). For other markers,
there was no significant association. When the Fisher exact test
was used to test the association between dichotomized marker
scores and clinical/pathological parameters, high ERK1/2 and
high VEGF-R2 expression were significantly correlated with more
advanced AJCC stage (P=0.043 for ERK, P= 0.004 for
VEGFR2) (Table 3). For all other markers, there was no
significant association between expression and clinical variables.
We next assessed the association between expression of each
marker and OS by Cox proportional hazards models. When
dichotomized AQUA scores were used, high FGF-R1 was
associated with lower hazards for OS (HR=0.75, 95% CI:
0.57–0.98, P=0.038), and VEGF-R1 and c-Kit had a trend
toward significance (HR=0.75, 95% CI: 0.56–1.00, P=0.052 for
VEFG-R1, HR=0.77, 95%CI: 0.59–1.02, P=0.073 for c-Kit)
(Table 4). Kaplan Meier curves are provided in Figure S1 in File
S1. No significant association was found for other markers. When
continuous AQUA scores were used in the univariate Cox
regression analysis, FGF-R1 remained significantly associated
with survival (P=0.004), and VEGF-R1 and c-Kit became
significant as well (P=0.012 and P=0.041, respectively)
(Table 4). Using multivariable Cox analysis, we found that high
FGF-R1, high VEGF-R1, and high c-Kit expression were also
independent predictors of better survival (P=0.0019 for FGF-R1,
P=0.0058 for VEGF-R1, and P=0.0205 for c-Kit) (Tables S6, S7
and S8 in File S1). The only other variables associated with OS by
multivariable analysis were ‘‘prior treatment’’ status and LDH for
FGF-R1 (P=0.0499 and P=0.0003, respectively), ‘‘site number’’
status and LDH for VEGF-R1 (P=0.0388 and P=0.0031,
respectively) and for c-Kit (P=0.029 and P=0.001, respectively).
All other variables included in the model were not associated with
OS.
Similar analysis was also conducted for PFS. When dichoto-
mized AQUA scores were used, univariate Cox regression showed
that high FGF-R1 and high EB1 were associated with lower
hazards (HR=0.76, P=0.0306 for FGF-R1; HR=0.77, P=0.05
for EB1), and MAP2 had a trend toward significance (HR=0.76,
P=0.0668) (Table 5). Kaplan Meier curves are provided in Figure
S2 in File S1. No significant association was found for other
markers. When continuous AQUA scores were used in the
univariate Cox regression analysis for PFS, FGF-R1 remained
significant (P=0.0174); MEK1 and MAP2 became significant as
well (P=0.041 and P=0.0294, respectively) (Table 5). VEGF-R2
had a trend toward significance (P=0.072). Multivariable Cox
analysis showed that FGF-R1 was also an independent predictor of
increased PFS (P=0.016) (Table S9 in File S1). No other variables
were associated with PFS on multivariable analysis.
B-Raf and N-Ras mutational status was available for 111 of
these patients, of whom 48 had B-Raf mutations and 26 had N-
Ras mutations. The sample size was small and the HRs for FGF-
R1, VEGF-R1 and c-Kit for survival and response were similar to
those shown for the entire cohort of patients (data not shown).
Discussion
Although the combination of sorafenib with carboplatin and
paclitaxel showed promising results in the phase I/II trial, two
subsequent double-blinded, randomized phase III studies did not
confirm the initial promise of this regimen, although a trend
towards a difference in OS and PFS between the two arms was
seen in patients with an elevated LDH (P= 0.094 and P=0.078,
respectively) [18,19,20,21]. In this retrospective biomarker study
we sought to measure levels of sorafenib targets as well as select
taxane targets, with the hope of further identifying a subset of
patients that might benefit from SCP or CP.
Table 2. Average level of expression for each biomarker (continuous AQUA scores) by clinical parameters.
AJCC Prior Therapy PS LDH
Marker Stage III M1a/1b M1c None IFN/IL2/GM-CSF One 1 0 Normal Elevated
B-Raf 42.3 43.6 47.9 47.1 43.9 47.9 45.8 45.6 46.2 45.5
c-Kit 37.1 37.0 40.2 39.8 37.5 36.8 39.3 37.6 38.7 39.0
C-Raf 26.6 24.4 26.2 27.1 23.7 27.0 26.1 24.7 25.4 26.5
FGF-R1 64.6 68.5 70 70.0 67.8 64.8 69.1 68.6 68.7 69.3
VEGF-R1 35.3 33.7 34.3 36.2 32.2 18.7 34.1 34.4 33.3 35.8
VEGF-R3 52.0 52.9 51.7 54.2 49.2 53.3 52.0 52.3 52.5 52.3
MEK1 39.5 39.7 40.7 42.1 38.0 32.2 41.1 38.5 41.7 38.5
PDGF-Rb 38.5 40.4 44.9 43.2 41.5 44.8 41.8 43.9 41.6 44.1
STMN1 50.8 54.5 57.7 57.1 54.5 50.2 55.6 56.1 55.7 56.6
MAP2 23.7 27.4 24.4 25.5 25.3 25.8 25.0 26.1 26.7 22.6
EB1 29.6 34.9 40.7 39.0 35.8 29.4 38.4 35.6 38.1 37.1
Bcl-2 26.4 27.2 25.9 28.6 23.5 33.0 26.3 26.7 26.3 27.3
ERK1/2 31.0 36.6 36.4 36.4 35.2 31.5 37.3 33.0 37.4 34.3
VEGF-R2 27.7 28.4 32.4 31.5 29.0 32.0 30.5 30.4 30.5 30.9
Note: significant correlations (P,0.05 for two-independent sample t test or analysis of variance test) are marked in bold.
doi:10.1371/journal.pone.0069748.t002
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We assessed associations between quantitative marker expres-
sion and response to therapy, PFS and OS, as well as with other
commonly utilized clinical and pathologic variables. To the best of
our knowledge, this is the largest prospectively collected melanoma
cohort from a multicenter trial that has studied marker expression
and its association with response to therapy, using continuous
output scores, rather than arbitrary pathologist-based divisions of
scores into high/low or strong/weak.
Our initial intention was to validate our previous observations of
associations between low ERK1/2 and high VEGF-R2 and
response to therapy seen in a subset of 44 patients treated in the
phase I/II trial with SCP. In this larger patient cohort we did not
confirm our previous findings. There are a number of possible
Table 3. Percentage of tumors with high expression for each biomarker by clinical parameters (AQUA scores dichotomized at the
median).
AJCC Prior Therapy PS LDH
Marker Stage III M1a/1b M1c None IFN/IL-2/GM-CSF One 1 0 Normal Elevated
B-Raf 42.3 45.5 54.8 52.5 45.8 75.0 51.1 48.0 51.9 48.8
c-Kit 48.2 45.1 53.5 55.0 44.1 40.0 50.3 49.4 49.6 51.7
C-Raf 69.2 42.7 50.4 53.9 45.1 40.0 52.4 45.4 48.2 54.4
FGF-R1 30.8 48.3 54.6 50.4 50.5 33.3 46.6 55.9 48.0 53.1
VEGF-R1 61.5 46.3 49.6 50.4 50.5 0.0 51.4 46.8 49.6 50.6
VEGF-R3 46.2 51.8 49.2 56.4 41.0 50.0 47.4 54.1 51.1 50.0
MEK1 44.0 52.0 49.6 53.6 45.7 25.0 51.8 46.3 53.9 45.4
PDGF-Rb 40.7 41.8 57.1 54.8 43.9 33.3 47.3 54.4 47.7 53.4
STMN1 50.0 42.0 54.7 51.4 48.9 25.0 49.2 50.7 51.7 49.3
MAP2 63.6 53.4 44.3 48.1 51.6 50.0 50.0 49.3 50.4 46.6
EB1 37.0 46.3 54.8 55.1 43.6 40.0 51.0 47.6 51.8 48.9
Bcl-2 44.0 46.9 52.8 52.8 44.7 80.0 50.3 48.8 50.7 50.6
ERK1/2 26.9 52.6 53.4 50.4 50.0 33.3 51.8 46.8 51.2 51.2
VEGF-R2 38.5 38.6 59.8 50.8 49.0 40.0 49.0 51.1 49.3 50.5
Note: significant correlations (P,0.05 for Fisher exact test) are marked in bold.
doi:10.1371/journal.pone.0069748.t003
Table 4. Univariate Cox regression analysis of dichotomized
and continuous AQUA scores for OS.
Dichotomized AQUA
Scores Continuous AQUA Scores*
Marker
Hazard
Ratio 95% CI P value
Hazard
Ratio 95% CI P value
B-Raf 0.89 0.66–1.19 0.4175 0.99 0.90–1.09 0.8185
c-Kit 0.77 0.59–1.02 0.0728 0.89 0.80–1.000.0410
C-Raf 0.93 0.70–1.23 0.5961 0.91 0.80–1.03 0.1470
FGF-R1 0.75 0.57–
0.98
0.0381 0.86 0.79–0.930.0004
VEGF-R1 0.75 0.56–
1.00
0.0517 0.88 0.80–0.970.0120
VEGF-R3 1.03 0.78–1.36 0.8274 0.98 0.91–1.06 0.6869
MEK1 0.94 0.71–1.26 0.6883 0.96 0.87–1.05 0.3228
PDGF-Rb 0.81 0.61–1.07 0.1421 0.92 0.83–1.02 0.1079
STMN1 1.09 0.80–1.48 0.5927 1.01 0.93–1.09 0.8337
MAP2 0.83 0.61–1.13 0.2359 0.95 0.88–1.03 0.1956
EB1 0.83 0.63–1.10 0.2028 0.97 0.90–1.05 0.4323
Bcl-2 1.05 0.80–1.39 0.7192 1.00 0.93–1.08 0.9552
ERK1/2 0.96 0.71–1.28 0.7564 0.95 0.88–1.03 0.2056
VEGF-R2 1.06 0.80–1.39 0.7012 0.95 0.83–1.08 0.4140
*Hazard ratios were calculated per 10-point change in AQUA scores.
doi:10.1371/journal.pone.0069748.t004
Table 5. Univariate Cox regression analysis of dichotomized
and continuous AQUA scores for PFS.
Dichotomized AQUA Scores Continuous AQUA Scores*
Marker
Hazard
Ratio 95% CI P value
Hazard
Ratio 95% CI P value
B-Raf 0.87 0.66–1.15 0.3399 0.95 0.87–1.04 0.2837
c-Kit 0.89 0.68–1.15 0.3666 0.93 0.83–1.03 0.1754
C-Raf 0.82 0.63–1.07 0.1482 0.97 0.85–1.10 0.6354
FGF-R1 0.76 0.59–
0.97
0.0306 0.90 0.83–0.98 0.0174
VEGF-R1 0.83 0.63–1.09 0.1775 0.93 0.85–1.02 0.1217
VEGF-R3 0.87 0.67–1.14 0.3126 0.97 0.90–1.04 0.3827
MEK1 0.84 0.64–1.10 0.2127 0.91 0.82–1.00 0.0410
PDGF-Rb 0.90 0.69–1.18 0.4410 0.95 0.86–1.05 0.2897
STMN1 0.95 0.71–1.26 0.7075 0.95 0.88–1.03 0.2393
MAP2 0.76 0.57–1.02 0.0668 0.92 0.86–0.99 0.0294
EB1 0.77 0.59–
1.00
0.0500 0.97 0.90–1.05 0.4902
Bcl-2 1.02 0.79–1.33 0.8687 1.00 0.93–1.07 0.9231
ERK1/2 1.13 0.86–1.49 0.3790 1.00 0.92–1.08 0.9709
VEGF-R2 0.99 0.77–1.29 0.9569 0.89 0.79–1.01 0.0722
*Hazard ratios were per 10-point change in AQUA scores.
doi:10.1371/journal.pone.0069748.t005
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explanations for this discrepancy. One possibility lies in the
differences in trial design. As opposed to the phase I/II study
which included a poorer prognosis group of patients (65% had
elevated LDH levels and patients could have had progression of
disease on up to five prior therapies), the phase III trial included
chemotherapy-naive patients, of whom less than half had received
prior immunotherapy, and 39% had elevated LDH levels. It is
possible that high ERK1/2 is a measure of disease aggressiveness
rather than response to therapy, and therefore more likely to have
predictive value in a more advanced disease population. This
hypothesis is supported by our previous studies on a historical
cohort of melanoma patients treated at Yale University, in which
we showed that high ERK1/2 is of prognostic value [22]. studies
of VEGF-R2 expression in this cohort showed no association with
survival, and in the phase I/II trial this marker was similarly not
associated with PFS or OS [22,29]. The other plausible
explanation for the lack of consistency with our previous findings
is the small size of the cohort in the early phase trials. The results
(high response rate and higher PFS than expected) were not
validated in the larger cohort used in this study, as is often the case
when early phase trials show promising results that are not
validated in larger randomized trials.
In the whole cohort of patients we found a statistically
significant association between high FGF-R1 and VEGF-R1 and
increased PFS and OS. Furthermore we found that expression of
FGF-R1 and VEGF-R1 was significantly higher in patients who
responded to therapy (CR+PR) than in non-responders (patients
with SD+PD+ un-evaluable). The fact that patients with high
FGF-R1 and VEGF-R1 were more likely to respond, is possibly
due to inhibition of cellular proliferation driven by both autocrine
loops, FGF2/FGF-R1 and VEGF/VEGF-R1. A number of
studies including ours have implicated high expression of both
FGF-R1 and VEGF-R1 in melanoma development and progres-
sion [29,30]. In other diseases over-expression of FGF2, the ligand
for FGF-R1, was shown to enhance apoptosis in MCF7 breast
tumor cells exposed to chemotherapy such as cisplatin or 5-
fluorouracil and to sensitize NIH 3T3 cells to apoptosis induced by
cisplatin [31,32], but this has not yet been proven to be the case for
metastatic melanoma.
Approximately 50% of metastatic melanomas harbor activating
B-Raf mutations, and 15–20% harbor activating N-Ras mutations
[5]. In this phase III trial, B-Raf mutational status was available
for 111 patients who also had specimens for AQUA analysis (48
had B-Raf mutations while 26 had N-Ras). Analysis of the
association between marker expression and OS or PFS in the
context of B-Raf or N-Ras mutational status yielded similar results
to the ones obtained in the whole cohort of patients. In vitro data
showed that sorafenib inhibits proliferation through MAPK
pathway inhibition and angiogenesis [33] and approximately
75% of patients have constitutive MAPK pathway activation. The
lack of efficacy of SCP in this phase III clinical study is likely due
to the fact that sorafenib is not a highly selective or a potent B-Raf
inhibitor; multiple sorafenib targets have been identified and many
probably remain unknown. In fact, in vitro enzyme inhibition
analyses show that the IC50 for mutated and wild-type B-Raf is 38
and 22 nmol/L respectively, while for VEGF-R2 it is 90 nmol/L
[9]. In recent years, other more selective and more effective
MAPK pathway inhibitors have emerged. Examples include
PLX4032 (RG7204/RO5185426/Vemurafenib, Genentech), a
selective inhibitor of mutant B-Raf, which was recently approved
for treatment of metastatic melanoma, GSK2118436 (Dabrafenib,
GlaxoSmithKline), a selective inhibitor of mutant B-Raf, and
GSK1120212 (Trametinib, GlaxoSmithKline), a MEK inhibitor,
which showed high response rates in patients with activating B-Raf
mutations [7,8]. Combinations of more selective MAPK pathway
inhibitors and chemotherapy or ipilimumab warrant further
evaluation. Another possible avenue worth investigating is the
combination of sorafenib and drugs that potentiate sorafenib
activity. In vitro studies have shown that certain inhibitors such as
the farnesyl transferase inhibitor, ionafarnib, or statins, such as
fluvastatin, can enhance sorafenib induced cytotoxicity in mela-
noma cells [34,35]. Given, however, that sorafenib is not void of
toxicities, and given the availability of more effective RAF and
VEGF-R2 inhibitors, careful consideration should be given to
clinical investigation of sorafenib-based combinations and thor-
ough pre-clinical studies are warranted prior to proceeding to
clinical trials.
Predictive biomarkers have not been previously studied for the
carboplatin and paclitaxel regimen in melanoma. Our results
suggest that the candidate biomarkers found here should be
further validated on additional patients treated with this regimen.
In addition, we note that given the design of this study, we are
unable to differentiate between predictive versus prognostic
biomarkers in this cohort, as there was no arm that did not
receive treatment. Of the biomarkers studied, the only one with
known predictive value for any systemic therapy is B-Raf
mutations in patients treated with inhibitors of mutant B-Raf
[6]. The presence of B-Raf mutations is also associated with poor
prognosis in metastatic melanoma [36,37].
In conclusion, an association was found between FGF-R1 and
VEGF-R1 expression and OS, PFS and response to carboplatin/
paclitaxel based therapy. Since sorafenib does not improve OS,
PFS or response rate when added to carboplatin and paclitaxel,
and seeing that carboplatin and paclitaxel use for melanoma has
increased in recent years, particularly for B-Raf wild-type
melanomas and patients who are not candidates for immune
therapy, these biomarkers should be validated in additional
cohorts, and their role as predictive versus prognostic biomarkers
should be clarified in untreated patients. Moreover, more active
and selective MAP kinase pathway inhibitors have recently
emerged along with other promising drugs such as ipilimumab,
and priority should be given to investigating such novel drugs or
combinations thereof in patients with metastatic melanoma and to
identifying biomarkers predictive of response to regimens with
greater anti-tumor activity than SCP.
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